Grifols S.A. American Depositary Shares (GRFS)
Stock · NASDAQ · Health Care
$7.64as of 10/16/2026
Price chart
Active signals
GRFS Signal Track Record
How signals performed across all stocks →What GRFS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | +2.3% | 58% | September 23, 2026 |
| Bollinger Band Breakdown | 25 | -3.4% | 40% | September 15, 2026 |
| Bollinger Band BreakoutActive now | 21 | -1.1% | 43% | July 20, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -6.2% | 37% | August 19, 2026 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 25,258
- Website
- www.grifols.com/
Fundamentals
- 1-day range
- $7.4$7.56
- Market cap
- $5.38B
- P/E (trailing)
- 12.88
- P/E (forward)
- 5.23
- EPS (trailing)
- $0.67
- Dividend yield
- 3.55%
- Beta
- 0.82
- Avg. volume
- 571.4K
- Ex-dividend date
- July 2, 2026
- Dividend pay date
- July 9, 2026
Forecasts
2 analyst ratings
Grifols S.A. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- GRFSGrifols S.A. American Depositary Shares$7.64▲ 1.33%Market cap $5.38BP/E 12.88$8.43$12.15
- MIRMMirum Pharmaceuticals Inc. Common Stock$80.14▼ 2.73%Market cap $5.74BP/E —$63.23$130
- AMRXAmneal Pharmaceuticals Inc. Class A Common Stock$19.18▼ 0.36%Market cap $5.76BP/E 39.88$9.56$21.18
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- ACADACADIA Pharmaceuticals Inc. Common Stock$19.12▼ 2.99%Market cap $4.87BP/E 8.79$18.39$30.96
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- DYNDyne Therapeutics Inc. Common Stock$14.25▼ 6.80%Market cap $4.83BP/E —$13.88$27.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GRFS Grifols S.A. American Depositary Shares | $5.38B | 12.88 | $7.64 | ▲ 1.33% | $8.43$12.15 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $5.74B | — | $80.14 | ▼ 2.73% | $63.23$130 |
| AMRX Amneal Pharmaceuticals Inc. Class A Common Stock | $5.76B | 39.88 | $19.18 | ▼ 0.36% | $9.56$21.18 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.87B | 8.79 | $19.12 | ▼ 2.99% | $18.39$30.96 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| DYN Dyne Therapeutics Inc. Common Stock | $4.83B | — | $14.25 | ▼ 6.80% | $13.88$27.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Are Options Traders Betting on a Big Move in Grifols Stock?Yahoo · 10/7/2026
- Grifols (BME:GRF) Stock May Be Below Fair Value On EarningsYahoo · 9/26/2026
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for WeekYahoo · 9/25/2026
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?Yahoo · 9/24/2026
- Grifols: Better Plasma Economics Can Unlock A Discounted EquitySeekingAlpha · 9/16/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 140.88M
- Total value held
- $1.13B
- Institutional holders
- 183
- Unknown36.33M
- Unknown22.92M
- Unknown19.35M
- Unknown8.39M
- Unknown5.01M
- Unknown4.33M
- Unknown3.29M
- Unknown3.16M
- Unknown2.99M
- Unknown2.86M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Options Traders Eye Potential Big Move in Grifols (GRFS)
Options traders are increasing activity around Grifols, suggesting they see a possible large price swing. The stock is trading near its 10‑touch support level of $7.90 and has a neutral RSI of 51.5, indicating no clear trend. Analysts value the shares around $10.87, while the 52‑week range tops $12.32, so a move could bring the price toward the upper end of that range.
Options Traders Eye Potential Big Move in Grifols (GRFS). Options traders are increasing activity around Grifols, suggesting they see a possible large price swing. The stock is trading near its 10‑touch support level of $7.90 and has a neutral RSI of 51.5, indicating no clear trend. Analysts value the shares around $10.87, while the 52‑week range tops $12.32, so a move could bring the price toward the upper end of that range.